Clinical DevelopmentImmunovant kicked off its first potentially registrational trial with IMVT-1402 in Graves’ disease patients who are hyperthyroid despite treatment with ATDs, indicating a proactive approach to addressing unmet needs.
Financial PositionThe company reported its cash position by the end of March at $714M, providing a runway through the GD readout expected in 2027.
Market PotentialShares appear cheap, and current levels offer an attractive entry point for long-term investors looking for a de-risked asset in what could be a ~$40B TAM.